-
Driving Innovation in Traditional Chinese Medicine: A Policy-Backed Renaissance
•
In Depth Analysis of Policy News in the Pharmaceutical Sector: A Comprehensive Guide to the Development and Industry Growth of Traditional Chinese Medicine New Drugs. 1. Rising Trends in Traditional Chinese Medicine New Drug Approval and Market Expansion The past year has witnessed a significant uptake in the approval of…
-
GE Healthcare Unveils Invenia ABUS Premium for Enhanced Dense Breast Screening
•
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced the launch of the Invenia Automated Breast Ultrasound (ABUS) Premium. This advanced 3D ultrasound system integrates artificial intelligence (AI) and innovative features to enable faster, reproducible supplemental screening and streamline exam readings for patients with…
-
Daiichi Sankyo Launches Datroway in Japan for HR Positive, HER2 Negative Breast Cancer
•
Japan-based Daiichi Sankyo (TYO: 4568) has announced the launch of Datroway (datopotamab deruxtecan) in Japan. The drug is approved for treating adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer who have undergone prior chemotherapy. First TROP2-Directed Therapy…
-
Porton Pharma Solutions’ Porton Advanced Partners with Eureka Therapeutics on T-Cell Therapies
•
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions’ subsidiary Porton Advanced, a specialist in advanced therapy medicinal products (ATMPs), has formed a partnership with US-based biotech firm Eureka Therapeutics, Inc. The collaboration focuses on the global clinical development of T-cell therapies, with financial details remaining undisclosed. Eureka Therapeutics’…
-
Triastek’s 3D-Printed T20G Receives US Clinical Approval for NOAC Treatment
•
China-based Triastek Inc., a pharmaceutical-focused 3D printing company, has announced receiving clinical approval in the US for its T20G. This 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) was previously cleared for trials in China in January of last year. T20G’s Technological AdvantagesT20G leverages Triastek’s patented 3D Microstructure for Gastric Retention…
-
Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment
•
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the US Food and Drug Administration (FDA) to market its Tremfya (guselkumab) as a treatment for moderately to severely active Crohn’s disease (CD). This IL-23 inhibitor now offers both subcutaneous (SC) and intravenous (IV) induction options…
-
Menarini Group Partners with VisualDx to Enhance BPDCN Identification Using AI/ML Tools
•
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has formed a partnership with US-based VisualDx. This alliance aims to enhance the identification of individuals who may have blastic plasmacytoid dendritic cell neoplasm (BPDCN) by introducing artificial intelligence/machine learning (AI/ML) tools. Understanding BPDCNBPDCN is an aggressive orphan hematologic malignancy with…
-
Elevation Oncology Halts EO-3021 Development After Poor Phase 1 Data
•
US-based Elevation Oncology, Inc. (NASDAQ: ELEV) has announced the decision to terminate development of EO-3021 following disappointing Phase 1 data, which caused its stock price to plummet 41% before trading. EO-3021’s Background and Licensing DealEO-3021, a Claudin 18.2-targeted antibody drug conjugate (ADC) originated by China’s CSPC Pharmaceutical Group Ltd (HKG:…
